Cargando…

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful tool for the detection/monitoring of alterations present in circulating tumor DNA (ctDNA). Plasma extracted from 171 patients with a variety of cancers was analyzed for ctDNA (54 genes and copy number variants (CNVs) in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwaederle, Maria, Husain, Hatim, Fanta, Paul T., Piccioni, David E., Kesari, Santosh, Schwab, Richard B., Banks, Kimberly C., Lanman, Richard B., Talasaz, AmirAli, Parker, Barbara A., Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891078/ https://www.ncbi.nlm.nih.gov/pubmed/26848768 http://dx.doi.org/10.18632/oncotarget.7110

Ejemplares similares

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
por: Villaflor, Victoria, et al.
Publicado: (2016)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer
por: Schwaederle, Maria, et al.
Publicado: (2015)

Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients
por: Schwaederle, Maria, et al.
Publicado: (2017)

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
por: Kato, Shumei, et al.
Publicado: (2015)

Cyclin alterations in diverse cancers: outcome and co-amplification network
por: Schwaederlé, Maria, et al.
Publicado: (2014)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology
por: Patel, Sandip P., et al.
Publicado: (2015)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics
por: Parish, A, et al.
Publicado: (2015)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
por: Charo, Lindsey M., et al.
Publicado: (2020)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
por: Helsten, Teresa, et al.
Publicado: (2015)

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
por: Mack, Philip C., et al.
Publicado: (2020)

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
por: Kim, Seung Tae, et al.
Publicado: (2017)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Clinical utility of circulating cell-free DNA in advanced colorectal cancer
por: Pereira, Allan A. Lima, et al.
Publicado: (2017)

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors
por: Piccioni, David E, et al.
Publicado: (2019)

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
por: Heestand, Gregory M., et al.
Publicado: (2017)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET)
por: Chang, Geraldine H., et al.
Publicado: (2018)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

HER2 expression status in diverse cancers: review of results from 37,992 patients
por: Yan, Min, et al.
Publicado: (2015)

Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types
por: Schwaederle, Maria, et al.
Publicado: (2015)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
por: Adashek, Jacob J., et al.
Publicado: (2021)

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
por: Lanman, Richard B., et al.
Publicado: (2015)

Genomic landscape of salivary gland tumors
por: Kato, Shumei, et al.
Publicado: (2015)

The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments
por: Boichard, Amélie, et al.
Publicado: (2020)

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
por: Sicklick, Jason K., et al.
Publicado: (2019)

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers
por: Vu, Peter, et al.
Publicado: (2020)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
por: Magbanua, Mark Jesus M., et al.
Publicado: (2022)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
por: Pham, Timothy V., et al.
Publicado: (2021)

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Case Report: Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy
por: Dhani, Harmeet, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b0911g089snae56ksmi0aehnaf